Host: Mouse
Target Protein: DM1
IR: Immunogen Range:
Clonality:
Isotype: IgG1
Source: DM1 coupled with OVA:
Purification: affinity purified by Protein A
Storage: PBS (pH7.4), 0.1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
Background:
Mertansine, also
called DM1 (and in some of its forms emtansine), is a thiol-containing
maytansinoid that for therapeutic purposes is attached to a monoclonal antibody
through reaction of the thiol group with a linker structure to create an
antibody-drug conjugate (ADC). Mertansine is a tubulin inhibitor, meaning that
it inhibits the assembly of microtubules by binding to tubulin (at the rhizoxin
binding site). The monoclonal antibody binds specifically to a structure
(usually a protein) occurring in a tumour, thus directing mertansine into this
tumour. This concept is called targeted therapy. Trastuzumab emtansine also
known as ado-trastuzumab emtansine and sold under the trade name Kadcyla, is an
antibody-drug conjugate consisting of the humanized monoclonal antibody
trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1.
Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor,
whereas trastuzumab emtansine undergoes receptor-mediated internalization into
cells, is catabolized in lysosomes where DM1-containing catabolites are
released and subsequently bind tubulin to cause mitotic arrest and cell death.
Trastuzumab binding to HER2 prevents homodimerization or heterodimerization
(HER2/HER3) of the receptor, ultimately inhibiting the activation of MAPK and
PI3K/AKT cellular signalling pathways. Because the monoclonal antibody targets
HER2, and HER2 is only over-expressed in cancer cells, the conjugate delivers
the cytotoxic agent DM1 specifically to tumor cells.
Size: 100ul
Concentration:
Applications: ELISA=1:5000-20000
Cross Reactive Species: (predicted: DM1)
For research use only. Not intended for diagnostic or therapeutic use.